ADCT
ADC Therapeutics S.A. (ADCT)
NYSE · Healthcare
ADC Therapeutics S.A. annual/quarterly shareholder equity history from 2022 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.
- ADC Therapeutics S.A. shareholder equity for the quarter ending December 31, 2025 were -185.8M, a 8.29% decrease year-over-year.
- ADC Therapeutics S.A. shareholder equity for 2025 were -185.8M, a 8.29% decrease from 2024.
- ADC Therapeutics S.A. shareholder equity for 2024 were -202.6M, a 36.69% increase from 2023.
- ADC Therapeutics S.A. shareholder equity for 2023 were -148.2M, a 286.59% decrease from 2022.
- ADC Therapeutics S.A. shareholder equity for 2022 were 79.5M.
Shareholder Equity
QUARTERLY · $B
YOY QUARTERLY GROWTH · %
| ADC Therapeutics S.A. Annual Shareholder Equity (Millions of US $) | |
|---|---|
| 2025 | $-186 |
| 2024 | $-203 |
| 2023 | $-148 |
| 2022 | $79 |
| ADC Therapeutics S.A. Quarterly Shareholder Equity (Millions of US $) | |
|---|---|
| 2025-12-31 | $-186 |
| 2024-12-31 | $-203 |
| 2023-12-31 | $-148 |
| 2022-12-31 | $79 |
ADC Therapeutics S.A. Shareholder Equity — FAQ
ADC Therapeutics S.A. (ADCT) shareholder equity over the last 4 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see ADCT's shareholder equity history?
The chart and table above show ADC Therapeutics S.A.'s shareholder equity by year and by quarter, including the growth rate.